Details, Fiction and QST4
MI-CP151 was a stage 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre research To judge several intravenous doses of sifalimumab, in Grownup sufferers with dermatomyositis or polymyositis (NCT00533091). Main trial targets have been to evaluate the security and tolerability of sifalimumab in dermatomyositis or polymyosit